Cost of Ultomiris for NMOSD may soon be reimbursable in Canada
Ultomiris, an approved infusion therapy for neuromyelitis optica spectrum disorder, is closer to being eligible for reimbursement in Canada.| Neuromyelitis News
Ultomiris, an approved infusion therapy for neuromyelitis optica spectrum disorder, is closer to being eligible for reimbursement in Canada.| Neuromyelitis News
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease that causes inflammation of the optic nerve and the spinal cord.| Neuromyelitis News
Category archive page for News.| Neuromyelitis News
Steve Bryson is a science writer for Neuromyelitis News with a PhD in biochemistry. He covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
